{"product_id":"can-a-lower-dose-of-everolimus-work-just-as-well-for-advanced-neuroendocrine-tumors","title":"Can a Lower Dose of Everolimus Work Just as Well for Advanced Neuroendocrine Tumors?","description":"\u003cp\u003eEverolimus, a targeted cancer drug, is normally given at 10 mg daily to treat advanced neuroendocrine tumors (NETs), but this dose causes serious side effects in roughly one in four patients. This retrospective study compared patients who took a higher dose (7–10 mg daily) versus a lower dose (5–6 mg daily) and found no significant difference in how long the tumors were controlled. Among 92 patients followed for a median of 4.2 years, the median time to treatment failure was 9.2 months for the higher-dose group and 7.2 months for the lower-dose group—a difference that was not statistically meaningful. The authors conclude that lower doses may be just as effective, with potentially fewer side effects and lower costs, and they have launched a randomized clinical trial (EVENET) to confirm these findings.\u003c\/p\u003e\n\u003ch1\u003eCan a Lower Dose of Everolimus Work Just as Well for Advanced Neuroendocrine Tumors?\u003c\/h1\u003e\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#why-this-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-everolimus\"\u003eEverolimus at a Glance: How the Drug Works\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#problem-with-standard-dose\"\u003eThe Problem with the Standard 10 mg Dose\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#who-was-in-study\"\u003eWho Was in the Study: Patient Characteristics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings-ttf\"\u003eKey Finding: Time on Treatment Before Failure\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings-os\"\u003eKey Finding: Overall Survival\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#side-effects-discontinuation\"\u003eSide Effects and Treatment Discontinuation\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#future-evnet\"\u003eThe Future: The EVENET Randomized Trial\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a retrospective study of 92 patients, lower-dose everolimus (5–6 mg daily) led to time to treatment failure similar to higher-dose (7–10 mg daily), with no significant difference.\u003c\/li\u003e\n\u003cli\u003eMedian time to treatment failure was 9.2 months for higher dose and 7.2 months for lower dose, but this difference was not statistically significant.\u003c\/li\u003e\n\u003cli\u003eOverall survival was not significantly different between dose groups after adjusting for age, tumor grade, and treatment line.\u003c\/li\u003e\n\u003cli\u003eLower dosing may cause fewer severe side effects and lower drug costs, especially for older or frailer patients, but this is not proven.\u003c\/li\u003e\n\u003cli\u003eA randomized phase II trial called EVENET is currently testing whether 10 mg daily and 5 mg daily are similar in controlling advanced neuroendocrine tumors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"why-this-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\u003cp\u003eNeuroendocrine tumors (NETs) are uncommon cancers that develop from neuroendocrine cells—cells that act like nerve cells and hormone-producing cells at the same time. These tumors can arise in the gastrointestinal tract (stomach, intestines, pancreas), the lungs, or other areas. When they cannot be removed by surgery and have spread (metastasized), they are called advanced NETs.\u003c\/p\u003e\n\u003cp\u003eFor many years, doctors have relied on a drug called everolimus to slow the growth of these tumors. The drug works by blocking a protein pathway inside cancer cells called the mTOR pathway, which tumors depend on to grow and multiply.\u003c\/p\u003e\n\u003cp\u003eThe catch is dosage. The only randomized trials that proved everolimus works used a dose of 10 mg taken by mouth once daily. That dose is effective, but it is also toxic. Nearly 25% of patients experience serious side effects—a number that climbs even higher in real-world settings, where patients tend to be older and sicker than those enrolled in clinical trials.\u003c\/p\u003e\n\u003cp\u003eThis study asked a practical question that matters directly to patients: \u003cstrong\u003eCan a lower dose—5 to 6 mg per day—control the tumor just as well as the standard 10 mg dose, while being easier for patients to tolerate?\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-everolimus\"\u003eEverolimus at a Glance: How the Drug Works\u003c\/h2\u003e\n\u003cp\u003eEverolimus is an oral medication that belongs to a class of drugs called mTOR inhibitors. The mTOR pathway acts like a switchboard inside cells, telling them when to grow and divide. In many NETs, this pathway is hyperactive, driving tumor growth.\u003c\/p\u003e\n\u003cp\u003eBy shutting down that switchboard, everolimus can slow or stop tumor progression. It is approved as a second-line or later treatment for patients with well-differentiated NETs of the gastrointestinal tract, lungs, or pancreas. Compared with a placebo (inactive pill), everolimus significantly extended the time patients lived without their cancer worsening—a measure called progression-free survival (PFS). This was demonstrated in patients with advanced pancreatic NETs and with gastrointestinal or lung NETs.\u003c\/p\u003e\n\u003cp\u003eThe drug works at multiple dose levels, but the treatment effect at lower doses was not previously well understood in daily practice.\u003c\/p\u003e\n\n\u003ch2 id=\"problem-with-standard-dose\"\u003eThe Problem with the Standard 10 mg Dose\u003c\/h2\u003e\n\u003cp\u003eThe standard approved dose of everolimus is 10 mg taken once daily. At that dose, clinically relevant side effects occur in about half of all patients in clinical trials. The most common side effects of any severity include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMouth sores (stomatitis):\u003c\/strong\u003e experienced by 65% of patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkin rash:\u003c\/strong\u003e experienced by 50% of patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInfections, diarrhea, nausea, and fatigue:\u003c\/strong\u003e each affecting roughly one-third of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSerious side effects—classified as grade 3 or higher, meaning severe or life-threatening—occur in a significant minority of trial participants. Specific grade 3+ rates from the randomized trials were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMouth sores: 9%\u003c\/li\u003e\n  \u003cli\u003eDiarrhea: 7%\u003c\/li\u003e\n  \u003cli\u003eInfections: 7%\u003c\/li\u003e\n  \u003cli\u003eAnemia (low red blood cell count): 6%\u003c\/li\u003e\n  \u003cli\u003eHigh blood sugar (hyperglycemia): 5%\u003c\/li\u003e\n  \u003cli\u003eFatigue: 3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eReal-world data show even higher rates of severe toxicity. Studies report everolimus-induced pneumonitis (an inflammatory lung condition) in nearly 20% of patients at any grade, with severe grade 3–4 pneumonitis in about 8%. The authors of this study previously published a multicenter review in which 22% of patients had severe (grade 3–4) infections, 6% had opportunistic infections (infections that take advantage of a weakened immune system), and 3.6% of patients died from treatment-related causes.\u003c\/p\u003e\n\u003cp\u003eWhy are real-world rates higher than trial rates? The authors explain that everyday patients tend to have more coexisting medical conditions (comorbidities) and are more fragile. They also may be followed for much longer—nearly double the follow-up time of the phase III trials (17–33 months)—giving side effects more time to emerge.\u003c\/p\u003e\n\u003cp\u003eFaced with this toxicity, clinical trials have always built in two dose-reduction steps: from 10 mg down to 5 mg daily, and from 5 mg daily down to 5 mg every other day. Treatment interruptions of up to 4 weeks are also allowed. Even with these maneuvers, side effects forced 12% to 24% of patients to stop everolimus entirely in the phase III trials.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\u003cp\u003eResearchers at two Brazilian cancer centers—A.C. Camargo Cancer Center in São Paulo and Hospital Moinhos de Vento in Porto Alegre—conducted this multicenter retrospective study. They identified patients by searching medical records from August 2011 to September 2023.\u003c\/p\u003e\n\u003cp\u003eTo be included, patients had to meet all of the following criteria:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAge 18 or older\u003c\/li\u003e\n  \u003cli\u003eHistologically confirmed, locally advanced, or metastatic NET that could not be removed surgically\u003c\/li\u003e\n  \u003cli\u003ePrimary tumor origins in the gastroenteropancreatic tract, lung, or unknown origin (if suspected to be gastroenteropancreatic based on pathology tests called immunohistochemistry)\u003c\/li\u003e\n  \u003cli\u003eWell-differentiated histology of any grade, using the 2019 World Health Organization (WHO) classification system\u003c\/li\u003e\n  \u003cli\u003eMeasurable disease according to the RECIST v1.1 criteria (a standardized way of measuring tumor response)\u003c\/li\u003e\n  \u003cli\u003eRadiologically progressive tumors before starting everolimus\u003c\/li\u003e\n  \u003cli\u003eAt least one dose of everolimus received\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients with NETs of gynecologic or urologic origins, and those with mixed neuroendocrine\/non-neuroendocrine tumors, were excluded. Patients with carcinoid syndrome (a condition caused by tumors secreting hormones) were allowed to take somatostatin analogs—medications that control hormone symptoms—at the same time as everolimus.\u003c\/p\u003e\n\u003cp\u003eBecause many patients who start at 10 mg daily later need their dose lowered, the investigators did something thoughtful. Instead of grouping patients by their starting dose, they calculated the \u003cstrong\u003emean (average) daily dose each patient actually took during the entire treatment duration\u003c\/strong\u003e. Patients were then divided into two groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigher-dose (HD) group:\u003c\/strong\u003e mean daily dose of 7–10 mg\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLower-dose (LD) group:\u003c\/strong\u003e mean daily dose of 6 mg or less\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe primary endpoint was \u003cstrong\u003etime to treatment failure (TTF)\u003c\/strong\u003e—the time from the first day of treatment until the tumor progressed, the drug was stopped because of toxicity or intolerance, or the patient died from any cause. TTF is a combined measure: it reflects both whether the drug is keeping the tumor in check and whether the patient can tolerate it well enough to keep taking it.\u003c\/p\u003e\n\u003cp\u003eThe investigators also measured \u003cstrong\u003eoverall survival (OS)\u003c\/strong\u003e as a secondary endpoint, calculated from the start of everolimus until death or last follow-up. Statistical analyses used Cox regression models to adjust for known prognostic factors: age, tumor grade, and line of therapy (whether everolimus was given as first\/second-line treatment or third-line and beyond). Two-sided p-values below 0.05 were considered statistically significant.\u003c\/p\u003e\n\u003cp\u003eDose reductions were made by the treating physician. They could be made upfront (for frailty or older age) or during treatment when side effects emerged. Notably, 55% of patients in the LD group had started at a higher dose and reduced it, while 45% began at a low dose from the start.\u003c\/p\u003e\n\u003cp\u003eThe study was approved by the ethics committee at each institution (A.C. Camargo Cancer Center approval code 5.949.520). Because of the retrospective design, signed informed consent from individual patients was not required.\u003c\/p\u003e\n\n\u003ch2 id=\"who-was-in-study\"\u003eWho Was in the Study: Patient Characteristics\u003c\/h2\u003e\n\u003cp\u003eA total of 92 patients were included. Of these, \u003cstrong\u003e74 patients (80%) were in the higher-dose (HD) group\u003c\/strong\u003e, taking a median daily dose of 10 mg (range 6.8–10 mg). \u003cstrong\u003e18 patients (20%) were in the lower-dose (LD) group\u003c\/strong\u003e, taking a median daily dose of 5.1 mg (range 4.7–6 mg).\u003c\/p\u003e\n\u003cp\u003eThe two dose groups were similar in most baseline characteristics, but there were two important differences:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge:\u003c\/strong\u003e Patients in the LD group were significantly older. The median age was 68 years (range 27–87) in the LD group versus 53 years (range 25–82) in the HD group (p = 0.007). This makes sense: frailer, older patients were more likely to start low or have doses reduced.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor grade:\u003c\/strong\u003e The LD group had more grade 3 tumors (28% versus 18%; p = 0.003). Grade 3 NETs are faster-growing tumors with higher Ki-67 proliferation indices.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOther baseline characteristics were balanced between groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSex:\u003c\/strong\u003e 63% of the HD group was male, versus 61% in the LD group (p = 0.8)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eECOG performance status\u003c\/strong\u003e (a measure of physical function, where 0 means fully active): In the HD group, 57% had a score of 0; in the LD group, 78% had a score of 0 (p = 0.1)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrimary tumor site:\u003c\/strong\u003e Pancreatic NETs in 58% of HD patients and 56% of LD patients; gastrointestinal or other origins in the remainder (p = 0.8)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment line:\u003c\/strong\u003e Everolimus was given as first or second-line therapy in 65% of HD patients and 56% of LD patients; 35% and 44% received it as third-line or later, respectively (p = 0.46)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEight patients (9% of the total) started everolimus at 5 mg from the beginning because of older age and\/or frailty; one of these patients needed a further reduction to 5 mg every other day.\u003c\/p\u003e\n\u003cp\u003eDose reductions during treatment (not upfront) were needed in 12 (16%) of HD patients and 10 (55%) of LD patients.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings-ttf\"\u003eKey Finding: Time on Treatment Before Failure\u003c\/h2\u003e\n\u003cp\u003eThe central result was a tie.\u003c\/p\u003e\n\u003cp\u003eAt a median follow-up of \u003cstrong\u003e4.2 years\u003c\/strong\u003e, the median time to treatment failure (TTF) was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e9.2 months\u003c\/strong\u003e (interquartile range [IQR]: 3.7–32) for the higher-dose (HD) group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e7.2 months\u003c\/strong\u003e (IQR: 3.9–27) for the lower-dose (LD) group\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe difference was not statistically significant (log-rank p = 0.85). In statistical terms, a p-value of 0.85 means there is an 85% probability that any observed difference arose purely by random chance—essentially, the two groups performed about the same.\u003c\/p\u003e\n\u003cp\u003eThe statistical analysis comparing the two groups directly confirmed this. The hazard ratio (HR)—a measure of how likely one group is to experience treatment failure at any given time compared with the other—was 1.24, with a 95% confidence interval (CI) of 0.68 to 2.25 and a p-value of 0.47. A hazard ratio of 1.24 suggests that LD patients failed treatment about 24% faster than HD patients, but the wide confidence interval (which spans from 0.68 to 2.25) crosses 1.0, meaning the difference cannot be distinguished from pure chance.\u003c\/p\u003e\n\u003cp\u003eAfter adjusting for age at the start of treatment (HR 1.02; 95% CI 1.01–1.04; p = 0.002), tumor grade when comparing grade 3 versus grade 1\/2 (HR 1.27; 95% CI 0.95–1.71; p = 0.11), and treatment line when comparing third-line or later versus first\/second-line (HR 1.55; 95% CI 0.92–2.62; p = 0.09), the dose group still showed no significant effect.\u003c\/p\u003e\n\u003cp\u003eThe authors performed an extra check. Because everolimus is formally approved only for patients with grade 1 or grade 2 NETs, they repeated the TTF analysis after excluding the 17 patients with grade 3 tumors. The results stayed similar: the median TTF was 5.3 months in the LD group versus 9.2 months in the HD group, again not statistically significant (log-rank p = 0.92). The median Ki-67 index—a marker of how fast tumor cells divide—in the excluded grade 3 group was 30%.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings-os\"\u003eKey Finding: Overall Survival\u003c\/h2\u003e\n\u003cp\u003eOverall survival (OS) also showed no statistically significant difference between dose groups, though the numbers tell a somewhat more complicated story.\u003c\/p\u003e\n\u003cp\u003eThe median overall survival was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6.5 years\u003c\/strong\u003e (IQR: 1.37–9.98) in the higher-dose group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3.6 years\u003c\/strong\u003e (IQR: 1.4–6) in the lower-dose group\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe difference was not statistically significant (log-rank p = 0.57). In plain language, although the HD group lived about 2.9 years longer on average, the broad overlap between the groups means we cannot confidently attribute that difference to the dose. The LD group, remember, was older and had more grade 3 tumors—factors that independently shorten survival.\u003c\/p\u003e\n\u003cp\u003eThe multivariable Cox model for overall survival confirmed this interpretation. It found that the following factors were independently associated with worse overall survival:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOlder age:\u003c\/strong\u003e HR 1.03; 95% CI 1.01–1.05; p = 0.007 (for each additional year of age)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 3 tumors\u003c\/strong\u003e (versus grades 1\/2): HR 1.68; 95% CI 1.15–2.47; p = 0.008\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEverolimus given in the third line or later:\u003c\/strong\u003e HR 2.15; 95% CI 1.05–4.34; p = 0.036\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBut the mean daily dose of everolimus itself was \u003cstrong\u003enot\u003c\/strong\u003e independently associated with survival: HR 1.32; 95% CI 0.56–3.13; p = 0.53. In other words, once you account for who the patients are (their age, tumor aggressiveness, and how many prior treatments they had), the dose of everolimus did not predict how long they lived.\u003c\/p\u003e\n\n\u003ch2 id=\"side-effects-discontinuation\"\u003eSide Effects and Treatment Discontinuation\u003c\/h2\u003e\n\u003cp\u003eSide effects drove treatment discontinuation in both groups, but the patterns differed by dose.\u003c\/p\u003e\n\u003cp\u003eIn the higher-dose group, \u003cstrong\u003e19 of 74 patients (25.7%) stopped everolimus\u003c\/strong\u003e for various reasons:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSixteen patients stopped because of severe toxicities\u003c\/li\u003e\n  \u003cli\u003eOne patient stopped due to logistics issues from the health care provider\u003c\/li\u003e\n  \u003cli\u003eOne patient chose to stop voluntarily\u003c\/li\u003e\n  \u003cli\u003eOne patient stopped after a surgical intervention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLooking in detail at the 16 HD patients who stopped for side effects, the toxicities included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFive patients with grade 3\/4 infections\u003c\/li\u003e\n  \u003cli\u003eFour patients with grade 3 pneumonitis (lung inflammation)\u003c\/li\u003e\n  \u003cli\u003eOne patient with grade 3 stomatitis (mouth sores)\u003c\/li\u003e\n  \u003cli\u003eOne patient with both grade 2 stomatitis and persistent grade 2 diarrhea\u003c\/li\u003e\n  \u003cli\u003eThree patients with grade 3 skin rashes (one also having grade 2 diarrhea)\u003c\/li\u003e\n  \u003cli\u003eOne patient with severe hepatic steatosis (fatty liver) accompanied by grade 3 liver enzyme elevation and grade 3 dyslipidemia (abnormal blood fats)\u003c\/li\u003e\n  \u003cli\u003eOne patient with grade 3 anemia (low red blood cells) and thrombocytopenia (low platelets)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn the lower-dose group, \u003cstrong\u003e4 of 18 patients (22.3%) stopped everolimus because of toxicities\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOne patient with grade 2 stomatitis\u003c\/li\u003e\n  \u003cli\u003eThree patients with grade 3 myelotoxicity (suppression of bone marrow function)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA crucial observation: there were \u003cstrong\u003eno toxicity-related deaths\u003c\/strong\u003e in either group in this study.\u003c\/p\u003e\n\u003cp\u003eThe percentages look similar at first glance (25.7% versus 22.3%), but the numbers require context. Most patients in the LD group arrived there because they could not tolerate the higher dose—55% had the dose reduced for toxicity and 45% were started low due to frailty. The fact that these fragile patients did not have higher discontinuation rates is itself a signal that lower doses may be better tolerated.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat These Findings Mean for Patients\u003c\/h2\u003e\n\u003cp\u003eThis study found no statistically significant difference between low-dose and high-dose everolimus for either time to treatment failure or overall survival. For patients, that possibility is valuable in three concrete ways.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst, quality of life.\u003c\/strong\u003e Everolimus at 10 mg daily brings several burdens—mouth sores in two-thirds of patients, rashes in half, and serious side effects in about a quarter of trial patients. Reducing adverse events not only helps patients feel better day-to-day; it also improves treatment adherence, because patients are more willing to continue a therapy they tolerate well.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecond, cost.\u003c\/strong\u003e In many countries, including Brazil, the price of everolimus is directly proportional to the dose. A patient taking 5 mg daily pays roughly half the drug cost of a patient taking 10 mg. The financial savings extend beyond the drug itself: fewer side effects mean fewer hospitalizations, doctor visits, laboratory tests, imaging scans, and additional medications to manage complications. This is especially important where health care resources are limited, such as in developing and underdeveloped countries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThird, an individualized approach.\u003c\/strong\u003e The ideal dose of everolimus for any given patient involves factors beyond the tumor itself—nutrition status, kidney function, and liver function all affect how the drug behaves in the body. Some of these factors vary among NET patients in ways that make them a distinctive population compared with other cancer types. For example, NET patients often have better kidney function than patients with renal cell carcinoma but more extensive liver metastases than patients with breast cancer.\u003c\/p\u003e\n\u003cp\u003eEvidence from a Japanese prospective study of patients with renal cell carcinoma found that patients who developed side effects had blood concentrations of everolimus after 8 days of treatment that were \u003cstrong\u003etwice as high\u003c\/strong\u003e as those who did not experience toxicity. In an early phase I clinical trial of everolimus in patients with solid tumors, certain toxicities—including low platelets, high blood sugar, and diarrhea—occurred \u003cstrong\u003eonly\u003c\/strong\u003e in the 10 mg daily group, not the 5 mg group.\u003c\/p\u003e\n\u003cp\u003eStudies in thyroid cancer, breast cancer, and mixed solid tumors have similarly linked higher blood levels of everolimus with greater toxicity.\u003c\/p\u003e\n\u003cp\u003eThe idea of routinely monitoring everolimus blood levels (therapeutic drug monitoring) is unlikely to be tested specifically in NET patients. This remains true because NETs are relatively uncommon and everolimus is now available as a generic drug worldwide. That is precisely why this kind of study—comparing clinically chosen lower doses against the standard dose—is important for guiding everyday care.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/h2\u003e\n\u003cp\u003eEvery study has limits, and this one has several honest ones worth knowing about.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe biggest limitation is the retrospective design.\u003c\/strong\u003e Researchers looked back at medical records rather than assigning patients randomly to a dose. Retrospective studies carry inherent risks of bias, including selection bias and confounding factors that may drive treatment outcomes.\u003c\/p\u003e\n\u003cp\u003eConcretely, the reasons patients received a lower dose were older age and frailty. That is exactly what the data show: the LD group was much older (median 68 versus 53 years) and had more grade 3 tumors. These are bad-prognosis features, which likely explains the shorter overall survival in the LD group in the unadjusted analysis. The statistical adjustments for age, treatment line, and NET grade tried to compensate, but no statistical model can fully remove this bias. Other unmeasured variables may still have influenced the results.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTTF is an unusual endpoint.\u003c\/strong\u003e Time to treatment failure is not a standard endpoint for evaluating solid tumor therapies; progression-free survival would be more typical. But TTF holds a special value here: it captures the net effect of treatment by combining both disease control and the patient's ability to tolerate therapy. Additionally, the authors note that in a retrospective chart review, progression-free survival is hard to estimate accurately because the intervals between imaging scans vary widely from patient to patient, and objective measurement of tumor responses and progression is often difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe sample size was modest.\u003c\/strong\u003e With 92 patients total—only 18 in the lower-dose group—the study may have been underpowered. That means it might have been unable to detect small but real differences between the dose groups. The wide confidence intervals (for example, HR for TTF ranging from 0.68 to 2.25) tell the same story: we cannot rule out a modest benefit or harm from lower dosing.\u003c\/p\u003e\n\u003cp\u003eFinally, this was not a study of a single dose. The \"lower dose\" group was defined loosely as a mean daily dose of 6 mg or less, and the actual doses varied. Clinical decisions about dose reductions were left to individual physicians, with no standardized protocols.\u003c\/p\u003e\n\u003cp\u003eDespite all these caveats, the authors emphasize that the results align with earlier phase I trial biology showing that 5 mg daily effectively inhibits the mTOR pathway, and they generate a strong hypothesis that deserves formal testing.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/h2\u003e\n\u003cp\u003eAuthors of a retrospective study are careful not to overreach. They present their suggestions as practical guidance informed by the data, not by definitive proof. Their recommendations are worth stating clearly:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor older and frailer patients:\u003c\/strong\u003e Starting everolimus at 5 mg daily is a sensible choice. The available evidence does not show a meaningful loss of disease control, while the lower starting dose is less likely to trigger the severe side effects that bedevil the 10 mg dose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor fit patients:\u003c\/strong\u003e Doctors can start treatment at the standard 10 mg daily, but they should take a flexible approach to dose intensity. Rather than waiting for a grade 3 or 4 toxicity to erupt, clinicians should reduce the dose to 5 mg daily as soon as grade 2 side effects appear.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor everyone:\u003c\/strong\u003e The results should not be interpreted as proof that 10 mg and 5 mg are perfectly interchangeable in every patient. The data support the possibility of near-equivalence, not equivalence. Individualized dose decisions, based on a patient's age, general condition, tumor grade, and how well they tolerate early side effects, remain essential.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eNo patient should change their everolimus dose on their own. Any dosage adjustment must be directed by the treating oncologist, who can weigh the specific details of that patient's disease and health status.\u003c\/p\u003e\n\n\u003ch2 id=\"future-evnet\"\u003eThe Future: The EVENET Randomized Trial\u003c\/h2\u003e\n\u003cp\u003eThe authors emphasize that their findings are hypothesis-generating—they set the stage for a more rigorous test, not a final answer. That test is already underway.\u003c\/p\u003e\n\u003cp\u003eThe EVENET trial is a randomized phase II trial designed to test near-equivalence between two doses of everolimus. It compares \u003cstrong\u003e10 mg daily versus 5 mg daily\u003c\/strong\u003e in patients with advanced, previously treated grade 1 or grade 2 gastroenteropancreatic or lung NETs. The trial registration number is \u003cstrong\u003eNCT06472388\u003c\/strong\u003e, and its primary endpoint is the progression-free survival rate at 12 months.\u003c\/p\u003e\n\u003cp\u003eIf the EVENET trial confirms what this retrospective study suggests, the implications would ripple outward. A strategy of lower-dose everolimus could effectively treat NETs with reduced toxicity, at lower cost, and could expand worldwide access to a drug that is already off-patent. For patients in countries with constrained health care budgets, that could be transformative.\u003c\/p\u003e\n\n\u003ch2\u003eConclusion\u003c\/h2\u003e\n\u003cp\u003eThis multicenter retrospective study of 92 patients with advanced neuroendocrine tumors found that a mean daily dose of 5–6 mg of everolimus produced a time to treatment failure statistically indistinguishable from the standard 7–10 mg dose (median 7.2 months versus 9.2 months; p = 0.85). Overall survival was also not significantly different after adjusting for age, tumor grade, and treatment line. Because lower-dose treatment is plausibly associated with less toxicity and lower costs, the authors conclude that everolimus at roughly 5 mg daily may offer a favorable balance of benefit and burden for selected patients—particularly older, frailer individuals. The randomized EVENET trial (NCT06472388) is now testing this hypothesis prospectively.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is everolimus and how does it work for neuroendocrine tumors?\u003c\/h3\u003e\n\u003cp\u003eEverolimus is an oral medication that blocks a protein pathway inside cancer cells called the mTOR pathway. This pathway helps tumors grow and multiply. By shutting it down, everolimus can slow or stop tumor progression. It is used for advanced well-differentiated neuroendocrine tumors of the gastrointestinal tract, lungs, or pancreas.\u003c\/p\u003e\n\u003ch3\u003eWhy is the standard 10 mg dose of everolimus a problem?\u003c\/h3\u003e\n\u003cp\u003eThe approved dose is 10 mg once daily. In clinical trials, serious side effects occur in about one in four patients. Common side effects include mouth sores in 65% of patients, skin rash in 50%, and infections, diarrhea, nausea, or fatigue in about a third. Real-world severe toxicity rates are even higher.\u003c\/p\u003e\n\u003ch3\u003eWhat question did this study ask about everolimus dose?\u003c\/h3\u003e\n\u003cp\u003eIt asked whether a lower dose of everolimus, about 5 to 6 mg daily, controls advanced neuroendocrine tumors just as well as the standard 7 to 10 mg daily dose. The study also considered whether lower dosing could cause fewer side effects and lower costs for patients.\u003c\/p\u003e\n\u003ch3\u003eHow did researchers compare the higher and lower dose groups?\u003c\/h3\u003e\n\u003cp\u003eThey reviewed records of 92 patients at two Brazilian cancer centers. They calculated the average daily dose each patient actually took during treatment, then divided patients into a higher-dose group (7–10 mg daily, 74 patients) and a lower-dose group (6 mg or less daily, 18 patients). Follow-up lasted a median of 4.2 years.\u003c\/p\u003e\n\u003ch3\u003eWhat does 'not statistically significant' mean in this context?\u003c\/h3\u003e\n\u003cp\u003eIt means the small difference between the dose groups could easily have happened by chance. This study could not prove that the lower dose is worse or better than the higher dose. It suggests the lower dose may be equally effective, but more research is needed to confirm.\u003c\/p\u003e\n\u003ch3\u003eShould I change my everolimus dose based on this study?\u003c\/h3\u003e\n\u003cp\u003eNo. Do not change your dose on your own. Any adjustment must be directed by your oncologist, who knows your cancer, age, overall health, and side effects. The authors suggest that older or frailer patients might sensibly start at 5 mg daily, but a randomized trial is still underway to confirm this.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion about lowering my everolimus dose from 10 mg to 5 mg for advanced neuroendocrine tumors?\u003c\/h3\u003e\n\u003cp\u003eIf your oncologist recommends the standard 10 mg daily dose but you are older, frail, or struggling with side effects, a second opinion can clarify whether a lower 5–6 mg dose is reasonable. In a study of 92 patients, the lower dose showed no statistically significant difference in time to treatment failure (7.2 vs 9.2 months) or overall survival after adjusting for age, tumor grade, and treatment line. Lower dosing may reduce toxicity and cost, but the evidence is retrospective and not definitive. Individualized decisions remain essential. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Efficacy of a lower dose of everolimus in advanced neuroendocrine tumors\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Rodrigo G. Taboada, Angelo B. Brito, Ana Luiza Silva, Rui F. Weschenfelder, and Rachel P. Riechelmann\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cancers, 2024, Volume 16, Article 3773\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.3390\/cancers16223773\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil; Oncology Service, Hospital Moinhos de Vento, Porto Alegre, Brazil\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudy timeline:\u003c\/strong\u003e Patients treated from August 2011 to September 2023\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval:\u003c\/strong\u003e A.C. Camargo Cancer Center review board, approval code 5.949.520\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e This study was not supported by any funding source.\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It was written for educational purposes and is not a substitute for individualized medical advice from a qualified health care professional.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47549385736348,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/es\/products\/can-a-lower-dose-of-everolimus-work-just-as-well-for-advanced-neuroendocrine-tumors","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}